Jim SkaggsChairman of the Board & CEO
Jim has been with Aminex since 2012. He was one of six top executives with NASA’s Apollo lunar landing program management, and he has spent almost 40 years in several corporate leadership positions in high-tech electronics systems, heavy infrastructure maintenance equipment manufacturing, and biotech drug development. Jim is retired chairman of Alamo Group, Inc. (NYSE) Prior to that, as chairman, CEO, and president of Tracor Inc., he led the turnaround and six times growth of Tracor in the defense electronics industry with 10,000 employees. Tracor was a Fortune 100 Fastest Growing Company. Jim graduated with a bachelor’s degree in mechanical engineering from the University of Washington and has received numerous honorary awards.
Roger Ulrich, PhDDirector
Dr. Roger Ulrich is an entrepreneur and biotech executive with more than 30 years of operational and administrative experience in the pharmaceutical industry. In addition to serving on the Board of Directors for Aminex, he is a member of the Board for Acerta Pharma BV, and served as the company’s Chief Scientific Officer until the majority acquisition by AstraZeneca in 2016. He is also on the Board for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several start-up companies. Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., acquired by Gilead in 2011, where he led the development of CAL-101 (GS-1101, idelalisib) now approved as Zydelig® for the treatment of patients with hematologic malignancies. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his pharmaceutical industry career he held positions at Michigan State and West Virginia Universities, and at Argonne National Laboratories. Dr. Ulrich holds several patents and has authored more than 120 publications. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.
Stacy Hock is a philanthropist and business owner. She serves on the boards of the Texas Public Policy Foundation, a leading state-based policy think tank, and the African Dream Initiative, educating tomorrow’s African leaders. Stacy recently transitioned off the boards of City Harvest, the largest food rescue organization in the country with over $100 million in revenue, and the Bowery Mission, serving the poor in New York City for nearly 150 years. Previously, Stacy held senior management positions in the software industry, including IBM’s WebSphere Software Services business for the Wall Street territory. She received her bachelor’s degree in computer science and electrical engineering from MIT and her MBA from the University of Texas.
Jeffery J. Miller PhD JDDirector
Jeff Miller retired as senior counsel of Perkins Coie’s licensing and technology group in 2014. He has since joined the Janicki family of companies in Skagit County, Washington as its Business Manager and General Counsel to two of them. His prior career included two successful IPOs, numerous private financings, many significant technology licensing transactions, and management of the FDA approval for an antibody-based cancer-imaging product. Jeff was also a partner in a Seattle patent law firm. Before joining Perkins Coie as senior counsel in 2008, Jeff served as CEO of NeuroTherapeutics, an early-stage company developing novel drugs to treat neurological diseases. Prior to that assignment, he was senior vice president of aQuantive, an Internet advertising company acquired by Microsoft. He earned a doctorate in biophysics from the University of California, Santa Cruz, and a JD from Loyola Law School in Los Angeles.
Rhonda has more than 25 years of experience in life sciences with both public and private industry companies, as well as experience as a clinical pharmacist. She is presently director, president, and CEO of Prevencio, Inc., a leading pioneer in the development of a multiplex cardiac proteomics blood biomarker test that assists ER physicians and cardiologists in assessing obstructive heart disease. Rhonda also serves as a board director for OtoNexus Medical Technologies, La Jolla Institute for Allergy & Immunology, and previously Washington Biotechnology and Biomedical Association (WBBA). She earned an MBA from UCLA and a bachelor’s degree in pharmacy from Washington State University.
Tom GrahamChief Operating Officer, Director
Tom Graham has served as a director or CEO of several companies, including three in the life sciences and drug discovery fields. In executive roles at Oridigm and MediQuest Therapeutics he authorized the early AMXT 1501/DFMO research program and worked directly on it with Dr. Mark Burns. He rejoined Mark at Aminex in 2011 and led its early funding and restructuring, including combining with his long time friend and business associate Jim Skaggs. Tom’s extensive business, entrepreneurial, and consulting experience spans multiple industries with both large and small companies. He received both his bachelor’s degree in mechanical engineering and MBA from the University of Washington.
Mark Burns, PhDPresident & Chief Scientific Officer, Director
Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.
Jack RoslingBoard Observer
Jack Rosling’s entrepreneurial history includes ownership and executive positions in the international steel trade, industrial raw materials, refrigerated warehousing, and drug development/diagnostics. With Tom Graham and Don Mowat, Jack was an active director of Bainbridge Sciences, Oridigm Corporation, MediQuest Therapeutics, and (until recently) Aminex Therapeutics. He received a bachelor’s degree in business administration and economics from Whitman College.